Publikationen, an denen er mitarbeitet Miguel Alcoceba Sánchez (15)

2023

  1. Systematic Evaluation of Antigenic Stimulation in Chronic Lymphocytic Leukemia: Humoral Immunity as Biomarkers for Disease Evolution

    Cancers, Vol. 15, Núm. 3

2022

  1. Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma

    Archives of pathology & laboratory medicine, Vol. 146, Núm. 7, pp. 862-871

  2. Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: Physiological immunomodulators or immune dysfunction

    Frontiers in Immunology, Vol. 13

2021

  1. Anti-trbc1 antibody-based flow cytometric detection of t-cell clonality: Standardization of sample preparation and diagnostic implementation

    Cancers, Vol. 13, Núm. 17

  2. The Hydropathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome

    Frontiers in Oncology, Vol. 11

2020

  1. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

    Blood Cancer Journal, Vol. 10, Núm. 10

  2. STAT3 and STAT5B mutations in T/NK-cell chronic lymphoproliferative disorders of large granular lymphocytes (LGL): Association with disease features

    Cancers, Vol. 12, Núm. 12, pp. 1-20

2018

  1. Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome

    Haematologica, Vol. 103, Núm. 7, pp. 1198-1208

  2. Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia

    Leukemia, Vol. 32, Núm. 12, pp. 2701-2705

  3. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

2017

  1. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma

    Journal of Molecular Diagnostics, Vol. 19, Núm. 1, pp. 99-106

  2. Host virus and pneumococcus-specific immune responses in high-count monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia: Implications for disease progression

    Haematologica, Vol. 102, Núm. 7, pp. 1238-1246

  3. The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy*

    Leukemia and Lymphoma, Vol. 58, Núm. 5, pp. 1144-1152

2008

  1. Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma

    British Journal of Haematology, Vol. 141, Núm. 2, pp. 212-215

2004

  1. Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation

    Haematologica, Vol. 89, Núm. 12, pp. 1421-1427